1Za T, Stefano VD, Rossi E, et al. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients[J]. BrJ Haematol, 2013, 160(5): 673-679.
2Teng H, Chopp M, Hozeska-Solgot A, et al. Tissue plasminogen activator and plasminogen activator inhibitor 1 contribute to sonic hedgehog-induced in vitro cerebral angiogenesis[J]. PLoS One, 2012, 7(3) :e33444.
3Urano T, Suzuki Y. Accelerated fibrinolysis and its propagation on vascular endothelial cells by secreted and retained tPA[J]. J Biomed Biotechnol, 2012, 208(1) :108-114.
4Knipe L, Meli A, Hewlett L, et al. A revised model for the secretion of tPA and cytokines from cultured endothelial cells [J].Blood, 2010, 116(12): 2183-2191.
5Suzuki Y, Yasui H, Brzoska T, et al. Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells [J]. Blood, 2011, 118(11): 3182-3185.
6Rosovsky R. , Hong F, Tocco D, et al. Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observationalstudy[J].Br J Haematol, 2013, 160(3): 351- 358.
7Brandal S, Blake CM, Sullenger BA, et al. Effects of Plasminogen activator inhibitor-t-specific RNAaptamers on cell adhesion, motility, and tube formation[J]. Nucleic Acid Ther, 2011, 21(6): 373-381.
9Ya g ci M, Sueak GT, Haznedar R. Fibrinolytic activity in multiple myeloma[J]. Am J Hematol, 2003, 74(4) : 231-237.
10Giatromanolaki A, Bai M, Margaritis D, et al. Hypoxia and activated VEGF/receptor pathway in multiple myeloma [J]. Anticancer Res, 2010, 30(7): 2831-2836.
2Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myelo- ma. Leukemia,2006 ; 20 (2) : 193 - 199.
3Yang S, XinX, Zlot C, et al. Vascular endothelial cell growth factor- driven ertdothelial tube formation is mediation by vascular endothelial cell growth factor-receptor-2, a kinase insert domain-containing re- ceptor. Arterioscler Thromb asc Bid ,2001 ;21 (12) :1934 - 1940.
4Numasaki M, Fukushi J, Ono M, et al. interleukin-17 promotes an- giogenesis and tumor growth. Blood, 2003 ; 101 (7) : 2620 - 2627.
5Honorati MC, Neri S, Cattini L, et al. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Carti- lage,2006;14(4) :345 -352.
6Nam JS, Terabe M, Kang M J, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor 'owth through interleukin-17. Cancer Res ,2008 ; 68(10) :3915 - 3923.
7Muranski P, Boni A, Antony PA, et al. Tumor-specific ThlT-polar- ized cells eradicate large established melanoma. BIood, 2008; 112 (2) :362 -373.
8Terpos E, Palermos J, Tsionos K, et al. Effect of pamidronate ad- ministration on markers of bane turnover and diseade aceiviry in mul- tiple myeloma. Eur J Haematol,2000 ; 65 ( 1 ) :331 - 336.
9Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer,2004 ; 4 (5) :349 - 360.
10Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mecha- nisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood ,2003 ; 101 (4) :1530.
4TSIRAKIS G, PAPPA C A, KAPAROU M, et al. The relationshipbetween soluble receptor of interleukin - 6 with angiogenic cyto-kines and proliferation markers in multiple myeloma[ J]. TumourBiol, 2013, 34(2) : 859 -864.
5NOBLE S, PASI J. Epidemiology and pathophysiology of cancerassociated thrombosis[ J]. Bri J Cancer, 2010, 102(1) : 2 -9.
6SOHN R H,DEMING C B,JOHNS D C, et al. Regulation of en-dothelial thrombomodulin expression by inflammatorycytokines ismediated by activation of nuclear factor kappa B [ J ]. Blood.
